
Vaccination plea after measles cases surge in Scotland
Health chiefs are warning of the risks of measles after more cases were recorded in Scotland in the first five months of the year than the whole of 2024.The latest figures, to be published on Thursday, could show more cases of the highly infectious disease, which is on the rise around the world.Two years ago there was just one case of measles in Scotland but last year that rose to 24 laboratory-confirmed cases.That figure was exceeded by 14 May this year and, although the numbers remain small, health experts are concerned that low vaccination rates in some areas could lead to many more cases.
Measles is a highly contagious disease which is spread by coughs and sneezes.The virus can lead to pneumonia, brain swelling and death.The World Health Organization said children under the age of five accounted for more than 40% of the cases reported in Europe and central Asia.In March, it reported that the number of measles cases in Europe was at its highest level for 25 years.WHO regional director Henri Kluge called it a "wake-up call"."Without high vaccination rates, there is no health security," he said.
Helen Benson, consultant in public Health for NHS Greater Glasgow and Clyde, said there had been an increase in cases across Scotland. "We have already seen more this year than the whole of last year," she said."In Glasgow we have seen several cases since the start of the year and in recent weeks we have seen a small number within the Govanhill area."We are potentially aware that there may be some transmission in the local community so our efforts now are to minimise the number of further cases."She said the health board was focusing its campaign on increasing levels of the MMR vaccine in the area.
The vaccine is generally given in two doses: the first between 12 and 15 months and the second at four to six years.Health experts says the vaccine - which immunises people against measles, mumps and rubella - is 97% effective in fighting off the dangerous virus. Uptake in Scotland remains high, with 90% of children having two doses by the age of six. However, WHO recommends at least 95% of children are vaccinated.Across Scotland vaccination rates have fallen slightly in recent years with public health officials believing vaccine fatigue or misinformation plays a role.Govanhill, one of the most diverse areas of Scotland, is one of several areas in Glasgow that has lower MMR vaccination rates.
Ms Benson said: "We've got a population that speaks many languages. For many English is not the first language. "So sometimes that has meant they may have had difficulty engaging with the NHS."She said the health board had launched a communication campaign across several languages and was using community peer workers to encourage people to take up the opportunity of any MMR vaccinations they may have missed."Measles can be a very serious infection," Ms Benson said."Approximately one in five cases end up in hospital. "Many of those may require intensive care, and it can lead to lifelong complications, for example, hearing loss, sight loss and inflammation of the brain."She said some people were more susceptible to complications from measles than others, including small babies under the age of one, pregnant women and people with immunosuppression."It is important to get the vaccine not just for yourself but for the people around you," she said.
Yvonne McAuley is one of the staff nurses who run the immunisation team which has set up a pop-up vaccine clinic in Govanhill.She said it can be difficult to get clients to come to an appointment because of barriers such as language, fear or misinformation. "We are very passionate about our job because we know what the outcome could be if the kids don't get immunised," she added.Ms McAuley said the team was doing everything it could to boost numbers, from providing interpreters and drop-in clinics to giving people who were afraid more time for their appointment.
Maryan Chaudhry and her husband Arfan Ali spoke to BBC Scotland News as they brought their one-year-old baby Liya for her MMR jab at the clinic."If it can benefit my child and her wellbeing, I will get it done," Maryan said. "It is to protect her."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Review Geek
2 hours ago
- The Review Geek
Has Dept. Q been renewed for Season 2? Here's what we know:
Renewed or Cancelled? Dept. Q is the latest crime drama on Netflix, created by Scott Frank, the brilliant mind behind The Queen's Gambit. With great characters and plotting, this one is not to be missed. Having watched the first season in its entirety, you may be wondering if this one has been renewed or cancelled. Well, wonder no more! What is Dept. Q about? Dept. Q is set in Edinburgh, follows Detective Chief Inspector Carl Morck, a brilliant but emotionally scarred officer recovering from a traumatic ambush that left his partner paralyzed and another officer dead. Relegated to a newly formed cold case unit in the police department's basement, Morck assembles a team of misfits to take on an old case involving the mysterious disappearance of prosecutor Merritt Lingard from a ferry four years prior. As the team delves deeper, they uncover a chilling conspiracy and psychological trauma that test their limits. We have extended coverage of Dept. Q on the site, including recaps of every episode HERE! Has Forget You Not been renewed for Season 2? At the time of writing, Dept. Q has not been renewed for season 2. Generally Netflix would gauge numerous metrics before renewing a show, including how many people initially watch it and then looking at the drop-off rate. With some shows, cancellations or renewals happen quickly. Other times, it can take months before a decision over a show's future is made. So far, Dept. Q has had a very good reaction online from critics and audiences alike. Given the way this show is set up, and the ending we receive, we're predicting that this will be renewed for a second season. The series has lots of potential, and it's also adapted from Jussi Adler-Olsen's Danish novels too so there's plenty of sourxe material to adapt. There's also lots of loose ends still to be tied up and plenty of potential for further cold cases to be brought up. We also know completion rate is a massive metric for these streamers and this feels like one of those shows that people will dive into and become hooked once they've watched a few episodes. However, we could be completely wrong too, so take our prediction with a pinch of salt! What we know about season 2 so far: Barely anything is known about Dept. Q season 2 at this point given Netflix haven't officially renewed or cancelled this one. Given the first season's conclusion, it does seem very likely to get the nod for another season. We'd likely get another 9 episode season if this one is renewed, along with a return of familiar cast and crew too. The story's tone and style will likely remain very similar to what we've been graced with in season 1, and a return of cast and crew along with Carl's quest for who the shooters were at Leith Park too. We will update this page when more information becomes available, so be sure to check this page out in the near future. Would you like to see Dept. Q return for a second season? What's been your favourite part of the show? Let us know your thoughts in the comments below!


Glasgow Times
3 hours ago
- Glasgow Times
Children and patients deserve to be safe in schools and hospitals
Around £1.2 billion – part of funding packages announced in last year's autumn budget – will be spent on repairing crumbling schools and hospitals across the country, the Government confirmed. Pupils at 656 schools and sixth forms will benefit from a share of this year's £470 million Condition Improvement Fund (CIF), used for projects like fixing crumbling roofs and removing asbestos. More than 400 hospitals, mental health units and ambulance sites will be handed £750 million to tackle problems such as leaky pipes, poor ventilation and electrical issues. Projects to deliver improvements to schools and hospital buildings will be delivered during the 2025/26 financial year, with the first upgrades to begin this summer, the Government has said. More than 100 schools, nurseries and colleges across England were forced to shut down days before the autumn term in 2023 amid concerns that classrooms and other buildings containing reinforced autoclaved concrete (Raac) were unsafe. Education Secretary Bridget Phillipson said: 'The defining image of the school estate under the previous government was children sitting under steel props to stop crumbling concrete falling on their heads. It simply isn't good enough. 'Parents expect their children to learn in a safe, warm environment. It's what children deserve and it is what we are delivering. Bridget Phillipson (Ben Whitley/PA) 'This investment is about more than just buildings – it's about showing children that their education matters, their futures matter, and this Government is determined to give them the best possible start in life.' Health Secretary Wes Streeting said: 'A decade and a half of underinvestment left hospitals crumbling, with burst pipes flooding emergency departments, faulty electrical systems shutting down operating theatres, and mothers giving birth in outdated facilities that lack basic dignity. 'We are on a mission to rebuild our NHS through investment and modernisation. 'Patients and staff deserve to be in buildings that are safe, comfortable and fit for purpose. Through our Plan for Change, we will make our NHS fit for the future.' A report by the National Audit Office (NAO) in January estimated it would cost around £13.8 billion to address the repairs and remedial work backlog for hospitals and other NHS properties in England, and an additional £13.8 billion to address the maintenance backlog across the school estate. Wes Streeting (Lucy North/PA) The Department for Education has confirmed a £2.1 billion investment for the school estate for 2025/26, almost £300 million more than the previous year. Paul Whiteman, general secretary at school leaders' union NAHT, described the funding boost for school buildings as a 'welcome start'. But he added: 'It is clear that much more Government investment and a long-term plan is needed to restore the school estate to at least a satisfactory condition.' Julia Harnden, funding specialist at the Association of School and College Leaders (ASCL), said: 'The wider problem is that there is a massive £13.8 billion maintenance backlog across the school estate and we are still nowhere near the level of investment needed to address this. 'The fact that schools and sixth form colleges have to bid for funding for urgent repairs and maintenance is in itself a sign of the inadequacy of overall investment and is effectively an annual exercise in papering over the cracks.'


North Wales Chronicle
3 hours ago
- North Wales Chronicle
New AI test could end ‘postcode lottery' for ‘game changer' prostate cancer drug
A study has found the technology can show medics the exact patients who will benefit most from a 'game changer' drug. Abiraterone is a type of hormone therapy that works by blocking the production of testosterone, the hormone that fuels the growth of prostate cancer. It is approved for use on the NHS in England for patients with advanced prostate cancer which has come back and spread to other parts of the body. However, it is not approved for men who are newly diagnosed with high-risk prostate cancer that has not yet spread, despite it being available for these patients in Scotland and Wales for the past two years. The new test, developed by Artera, uses AI to pick up features invisible to the human eye on images of tumour samples. The study, led by The Institute of Cancer Research, London, and University College London (UCL), ran the test on biopsy images from more than 1,000 men who took part in the Stampede trial. Patients were given a score of either biomarker-positive or biomarker-negative. Researchers found abiraterone reduced the risk of death among biomarker-positive patients from 17% to 9%. In biomarker-negative patients, the drug cut death risk from 7% to 4%, with researchers suggesting this indicates these men would benefit from standard therapy. Nick James, a professor of prostate and bladder cancer research at The Institute of Cancer Research, London, and consultant clinical oncologist at The Royal Marsden NHS Foundation Trust, is chief investigator of Stampede and co-led the new study. He said: 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy. 'Access to this life-extending drug is currently a postcode lottery – with those living in Scotland and Wales able to receive the treatment for free. 'The NHS in England has previously decided that it would be too expensive to offer the drug. Since the patent expired in 2022, abiraterone costs just £77 per pack – compared with the thousands of pounds that new drugs cost. 'Previous research by my team has shown that preventing cancer relapses for these men would save more money than the drug costs to purchase. 'I truly hope that this new research – showing precisely who needs the drug to live well for longer – will lead to NHS England reviewing their decision not to fund abiraterone for high-risk prostate cancer that has not spread.' Prof James also highlighted that while abiraterone can have 'spectacular' results, it does have side effects. 'Abiraterone has already hugely improved the outlook for hundreds of thousands of men with advanced prostate cancer,' he said. 'We know that for many men with cancer that has not yet spread, it can also have spectacular results. 'But it does come with side effects and requires additional monitoring for potential issues with high blood pressure or liver abnormalities. 'It can also slightly increase the risk of diabetes and heart attacks, so knowing who is most likely to benefit is very valuable.' Experts hope the findings, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, may lead to a change in the availability of abiraterone in England. Prof Kristian Helin, chief executive of The Institute of Cancer Research, said the drug has been a 'game changer for treatment of prostate cancer'. 'Alongside our mission to find smarter, kinder treatments, we must ensure we are matching the right drugs to the right patients,' he added. 'This research, using artificial intelligence, provides an innovative route to testing prostate cancer patients to determine their treatment. 'I hope that this can be implemented so that all men with prostate cancer who will benefit from abiraterone can do so.' Dr Matthew Hobbs, director of research at Prostate Cancer UK, said: 'Prostate Cancer UK has been calling on the UK Government to approve this life-saving, cost-effective drug for over two years. 'These exciting results suggest a way to make this an even more cost-effective approach. 'We therefore echo the researchers' urgent call for abiraterone to be made available to those men whose lives it can save – men who, thanks to this research, we can now identify more precisely than ever before.' A Department of Health and Social Care spokesperson said: 'We understand the frustration and upset of patients who cannot access this treatment. 'Abiraterone is available for some NHS patients in England with metastatic prostate cancer, and a decision to extend its use will be kept under review.'